The in vitro choice_O.Nicolas_2013

498 views

Published on

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
498
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The in vitro choice_O.Nicolas_2013

  1. 1. RETOS Y TENDENCIAS EN DRUG DISCOVERY JOSEP ORIOL NICOLÁS i PALLEJÀ, PhD CEO
  2. 2. ABOUT US Chemical Pharma 25% FACTURACIÓN 10% EBITDA 97% CLIENTES INT. Cosmetics Food industry
  3. 3. DISCOVERY OVERVIEW
  4. 4. DISCOVERY OVERVIEW B? A? C? D? SAFETY A? B? C? D? Therapeutic BENEFICIO BENEFIT Terapeútico Long and costly process to reach requirements of: • Positive balance between therapeutic efficacy and safety • Optimal cost-effectiveness for administration in humans and commercialization Toxic RIESGO RISK Tóxico
  5. 5. DISCOVERY OVERVIEW
  6. 6. DISCOVERY OVERVIEW • Pérdida de 56 M€ debido al negocio farmacéutico • Focalización en área de dolor • Cierre de la compañía • Focalización en respiratoria y derma área
  7. 7. DISCOVERY OVERVIEW
  8. 8. DISCOVERY OVERVIEW Facturación por país (Share %) UK Alemania 3% 2% 3% USA España Italia 13% 44% Suiza Italia Bélgica Singapur Francia Holanda Finlandia Japón 30%
  9. 9. DISCOVERY & DEVELOPMENT OPTIMIZATION • FOCALIZACIÓN EN UN ÁREA TERAPÉUTICA CONCRETA • DISMINUCIÓN DEL ENDEUDAMIENTO DERIVADO DE ACTIVIDADES DE R+D+I • INCREMENTO DEL OUTSOURCING EN R+D • DRUG REPROFILING • IN/OUT LICENSING • ENFERMEDADES HUÉRFANAS • ADQUISICIÓN DE COMPAÑÍAS BIOTECNOLÓGICAS INNOVADORAS • INVERSIÓN O APUESTA POR MÉTODOS “RENTABLES”: PREDICTORES DE RESPUESTA A FÁRMACOS, IN SILICO, IN VITRO.
  10. 10. IN VITRO ADME MARKET
  11. 11. IN VITRO ADME MARKET • Recorte tiene su objetivo en RD • Reestructuración tiene su objetivo en la RD • Inversión tiene objetivo en la RD • Rentabilización de la RD
  12. 12. OUR PROPOSAL
  13. 13. PROFITABILITY
  14. 14. OUR PRODUCTS: READY-TO-USE TECHNOLOGY READY TO USE TECHNOLOGY™ “…EASING HANDLING AND SHIPPING…” Patented solid shipping medium Careful manipulation Available in 24/96 multi-well format
  15. 15. OUR PRODUCTS: ADVANTAGES Avoiding variability due to the cell culture High reproducibility among batches Careful manipulation Available in 24/96 multi-well format
  16. 16. OUR PRODUCTS: RANGES Differentiated Caco-2 cell barrier Differentiated coculture Caco-2 and human goblet cells MDCKII monolayer expressing MDR1, BCRP, BCRP_OATP2B1 Transporters HepG2 single transduced with different CYP450: 3A4, 1A2, 2E1, 2A6
  17. 17. PIPELINE Viability study BBB KIT Sebocyte cell model Models for nanosafety Preadyport-BCRP/OATP2B1 Preadyport-Other Transporters Ready-to-use hepatocytes Ready-to-use Adipocytes Definition and Development Proof of Concept Validation Commercializat.
  18. 18. www.readycell.com www.leitat.org reagents@readycell.com

×